• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by OceanTech Acquisitions I Corp.

    11/13/23 4:00:41 PM ET
    $OTEC
    Blank Checks
    Finance
    Get the next $OTEC alert in real time by email
    NT 10-Q 1 g083849_nt10q.htm NT-10Q

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

     

    (CHECK ONE): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D
      o Form N-CEN o Form N-CSR      

     

     

    Commission File Number: 001-40450
       
      For Period Ended:  September 30, 2023
       
      o Transition Report on Form 10-K
      o Transition Report on Form 20-F
      o Transition Report on Form 11-K
      o Transition Report on Form 10-Q
      o Transition Report on Form N-SAR
      For the Transaction Period Ended: ______________

     

     

    READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION

     

    OceanTech Acquisitions I Corp.

    Full Name of Registrant

     

    Former Name if Applicable

     

    515 Madison Avenue, Suite 8133

    Address of Principal Executive Office (Street and Number)

     

    New York, New York 10022

    City, State and Zip Code

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

        (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    x   (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN, Form N-CSR or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
        (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

      

     

     

     

       

     

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    OceanTech Acquisitions I Corp. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (the “Q3 2023 Form 10-Q”) by the prescribed due date because the Company is in the process of preparing the financial statements for the quarter ended September 30, 2023 and will need additional time to complete such financial statements. The Company anticipates that it will file its Q3 2023 Form 10-Q within the five-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification: 

     

    Suren Ajjarapu   929   412-1272
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ý Yes  o No
       
       
     
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  o Yes   ý No
       
       
     
     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    OceanTech Acquisitions I Corp.

    (Name of Registrant as Specified in Charter)

     
    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Date: November 13, 2023 By: /s/ Suren Ajjarapu                           
      Name: Suren Ajjarapu
      Title: Chief Executive Officer
    (Principal Executive Officer)

     

     

     

     

       

    Get the next $OTEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTEC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OceanTech Acquisitions I Corp. Announces Redemption of Shares

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 30, 2023, at the special meeting of the stockholders of the Company, holders of 1,035,788 shares of Class A common stock of the Company (the "Redeeming Stockholders") exercised the right to redeem such shares. On June 2, 2023, the Company made cash payments to the Redeeming Stockholders totaling $11,233,820 representing approximately $10.84 per share. Following such payments to the Redeeming Stockholders, the Company's trust account had a balance of approximately $8,814,443. About OceanTech Acquisitions I Corp. OceanTech is a blank check company

    6/7/23 9:29:00 AM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. Announces Postponement of Special Meeting of Stockholders Until May 30, 2023 at 11:30 a.m. EDT

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, previously filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Friday, May 26, 2023 at 1:00 p.m. EDT (the "Special Meeting") to vote on, among other things, a proposal to approve an amendment to OceanTech's amended and restated certificate of incorporation to extend the date by which OceanTech must consummate its initial business combination from June 2, 2023 by up to twelve (12) one-month extensions through June 2, 2024, or such earlier date as determined by OceanTech's board of directors. The Company is

    5/25/23 11:09:00 PM ET
    $OTEC
    Blank Checks
    Finance

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    SEC Filings

    View All

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 4:52:09 PM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)

    2/13/24 4:50:55 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/30/24 4:06:26 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Owl Creek Asset Management, L.P.

    4 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    6/1/23 9:18:13 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Aspire Acquistion Llc

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/25/23 1:02:27 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Fell Donald G.

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/21/23 6:27:45 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 5:54:33 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/5/24 2:07:43 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/10/24 11:01:25 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Financials

    Live finance-specific insights

    View All

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance